Advances in Drug Design of Radiometal-Based Imaging Agents for Bone Disorders
International Journal of Molecular Imaging · 2011
DOI: 10.1155/2011/537687 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Imaging, 2011. Verfasst von Kazuma Ogawa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmaceutical Sciences, Graduate School of Natural Science and Technology, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Nuclear medicine bone imaging has been the optimum diagnosis for the detection of bone disorders because the lesion could be detectable before the appearance of symptomatic and radiographic changes. Over the past three decades, 99m Tc-MDP and 99m Tc-HMDP have been used as bone scintigraphic agents because of their superior biodistribution characteristics, although they are far from optimal from a chemical and pharmaceutical point of view. Recently, a more logical drug design has been proposed as a concept of bifunctional radiopharmaceuticals in which the carrier molecules (bisphosphonates) and radiometal chelating groups are separated within a molecule, specifically, 99m Tc-mononuclear complex-conjugated bisphosphonate. Some of the 99m Tc-mononuclear complex-conjugated bisphosphonate compounds showed superior biodistribution in preclinical studies. Moreover, the drug design concept could be applied to 68 Ga PET bone imaging agents. These studies would provide useful information for the development of radiometal-based imaging and therapeutic agents for bone disorders such as bone metastases.
Autor:innen und Institutionen
- Division of Pharmaceutical Sciences, Graduate School of Natural Science and Technology, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan.
Zitieren
APA
Ogawa, K., & Saji, H. (2011). Advances in Drug Design of Radiometal-Based Imaging Agents for Bone Disorders. International Journal of Molecular Imaging. https://doi.org/10.1155/2011/537687
Vancouver
Ogawa K, Saji H. Advances in Drug Design of Radiometal-Based Imaging Agents for Bone Disorders. International Journal of Molecular Imaging. 2011. doi:10.1155/2011/537687
BibTeX
@article{Ogawa2011,
author = {Ogawa, Kazuma and Saji, Hideo},
title = {Advances in Drug Design of Radiometal-Based Imaging Agents for Bone Disorders},
journal = {International Journal of Molecular Imaging},
year = {2011},
doi = {10.1155/2011/537687}
}
EUVIMED